To the Editor Dr Abdel-Wahab and colleagues1 reported a head-to-head comparison between currently available bioprostheses for transcatheter aortic valve replacement (TAVR). In the Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve vs Edwards SAPIEN XT (CHOICE) trial, a higher rate of device success was obtained with a balloon-expandable prosthesis than with a self-expanding prosthesis. This finding was partly driven by “a lower frequency of residual more-than-mild paravalvular aortic regurgitation. . . .” However, we believe that some limitations hamper this interpretation, particularly with regard to the assessment of postprocedural paravalvular regurgitation.
Barbanti M, Capodanno D, Tamburino C. Bioprosthetic Valves for Transcatheter Aortic Valve Replacement. JAMA. 2014;312(8):843-844. doi:10.1001/jama.2014.8359